A carregar...
THE RISE AND FALL OF GAKEKEEPER MUTATIONS? THE BCR-ABL1(T315I) PARADIGM
The use of tyrosine kinase inhibitors (TKIs) has become an integral component of cancer therapy. Imatinib mesylate (Gleevec), a BCR-ABL1 inhibitor, was the first TKI approved in cancer medicine and has served as a model for the development of similar agents for other cancers. An important drawback o...
Na minha lista:
| Publicado no: | Cancer |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2011
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6896214/ https://ncbi.nlm.nih.gov/pubmed/21732333 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.26225 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|